# Phase I Study of Safety and Immunogenicity of AMA1-C1Alhydrogel + CPG 7909 Vaccine for Malaria

> **NCT00414336** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 150 (—)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** AMA1-C1/Alhydrogel + CPG 7909 Vaccine

## Key facts

- **NCT ID:** NCT00414336
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12-15
- **Primary completion:** 2006-12-15
- **Final completion:** 2006-12-15
- **Target enrollment:** 150 (—)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00414336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00414336, "Phase I Study of Safety and Immunogenicity of AMA1-C1Alhydrogel + CPG 7909 Vaccine for Malaria". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00414336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*